Viral Vector p11 Gene Therapy for Depression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of psychiatric disorders, particularly depression, is limited due to the lack of identified genes and gene products suitable for gene therapy, and existing treatments have limitations in efficacy and specificity.
Innovation Solution
Development of a viral vector carrying p11 nucleic acid, specifically designed to increase p11 levels in the nucleus accumbens of the brain, either through gene therapy or in conjunction with other treatments, to treat psychiatric disorders and improve treatment responsiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If p11 is overexpressed throughout the brain using traditional transgenic approaches, then p11 levels increase, but generalized hyperactivity is induced
Solution Approach 1:
The patent applies local quality by using a viral vector system that enables region-specific expression of p11 in the nucleus accumbens, while other brain regions maintain normal p11 levels. This spatial differentiation resolves the contradiction by concentrating the therapeutic effect in the depression-relevant nucleus accumbens region, avoiding the generalized hyperactivity that occurs with whole-brain overexpression.
2Adaptability or versatility
If conventional antidepressant treatments are administered, then treatment coverage is broad, but efficacy is limited and non-specific
Solution Approach 1:
The patent segments the treatment approach by combining conventional antidepressant medication with a targeted gene therapy component delivered via viral vector to the nucleus accumbens. This segmentation allows the pharmacological treatment to maintain broad coverage while the localized genetic modification provides enhanced specificity and efficacy in the depression-relevant brain region, thereby resolving the contradiction between broad coverage and targeted effectiveness.
Data Source
AI summary
The invention provides materials and methods for p11-mediated therapy of psychiatric disorders. The invention provides vectors for increasing p11 expression and methods of treating a mammal with one or more symptoms of a psychiatric disorder. The invention also provides methods for improving a mammal's responsiveness to treatment for a psychiatric disorder. The invention further provides model animals for depression and depression therapy.